The addition of evolocumab to statin therapy in individuals with angiographic coronary disease appeared to encourage coronary atherosclerosis regression, as demonstrated in the GLAGOV* trial presented at the Scientific Sessions of the American Heart Association (AHA 2016) held in New Orleans, Louisiana, US.
Prophylactic infusion of levosimendan did not reduce death or perioperative myocardial infarction or the need for dialysis or mechanical cardiac assist device more than placebo in patients at risk for low cardiac output syndrome undergoing cardiac bypass. However, it increased cardiac output and reduced low cardiac output syndrome, according to primary findings of the LEVO-CTS* trial.
The phosphodiesterase 3 inhibitor cilostazol may prevent secondary stroke in individuals with a recent history of ischaemic stroke. However, there was a higher incidence of myocardial infarction in this group, according to findings of the PICASSO* study presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas, US.